Heyholder

CJ Bioscience Disclosures

311690 · KOSDAQ

Disclosures

2 total · 20 per page

Newest first

Periodic Report

CJ Bioscience sold KRW 0.9 billion in Q3 and lost KRW 4.9 billion from its main business, a smaller loss than KRW 6.1 billion a year earlier.

Paid-in Capital Increase Decision

Subsidiary EzBiome will issue 185,667 new shares at KRW 40,671 each to raise KRW 7.3 billion for debt repayment and KRW 0.3 billion for operations.

Catch the next disclosure fast

Get app alerts for new disclosures from CJ Bioscience.